Hemoglobin, Albumin, Lymphocyte, and Platelet (HALP) score as a biomarker for phase differentiation in Peyronie’s Disease: a retrospective cohort study

Abstract

Abstract Background Peyronie’s disease progresses through acute (inflammatory) and chronic (fibrotic) phases. Objective biomarkers for phase differentiation are lacking. Neutrophil-to-eosinophil ratio has been evaluated as an inflammatory marker in PD and reported as an important marker in the inflammatory phase. We evaluated the Hemoglobin, Albumin, Lymphocyte, and Platelet score as a non-invasive indicator of Peyronie’s Disease phases. Results A retrospective cohort of 216 Peyronie’s disease patients were analyzed. Blood parameters were collected at diagnosis (acute phase) and follow-up (chronic phase) in 112 patiens. Hemoglobin, Albumin, Lymphocyte, and Platelet scores were compared using receiver operating characteristic curves and paired t-tests. Hemoglobin, Albumin, Lymphocyte, and Platelet scores increased significantly from 36.8 ± 8.2 (acute) to 47.5 ± 10.4 (chronic) in 112 paired patients (p 41.2 for chronic phase detection (area under the curve = 0.83, sensitivity 76%, specificity 71%, positive predictive value 73.9%). Conclusion The Hemoglobin, Albumin, Lymphocyte, and Platelet score is a cost-effective tool for differentiating Peyronie’s Disease phases, aiding clinical decision-making.

Keywords

• Peyronie’s disease
• HALP score
• Inflammatory indices
• Fibrosis
• Biomarker